about
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: role of platelet kinetics in a single-centre long-term study.Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years.Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells.Treg therapy in transplantation: a general overview.Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study.Reduced TCR-signalling contributes to impaired Th17 responses in tolerant kidney transplant recipients.Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and SplenomegalyAn Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment.The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System.Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis.Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice.Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34 CellsPast, Present, and Future of Regulatory T Cell Therapy in Transplantation and AutoimmunityIL-36 Promotes Systemic IFN-I Responses in Severe Forms of PsoriasisExpanded Regulatory T Cells Induce Alternatively Activated Monocytes With a Reduced Capacity to Expand T Helper-17 CellsApplicability, safety, and biological activity of regulatory T cell therapy in liver transplantation
P50
Q33416947-BC58D717-B6B7-4C44-8CF5-6DDA12B6745EQ33429426-6F69C7EC-402C-4280-9E38-9AC5C7B548BEQ36420758-EDA70870-15B1-4716-9524-350D8399515FQ38778543-B953BD18-365F-4E43-B490-458D1DAD5690Q39986585-C3457B14-BBF7-4C29-98EA-6A048F0F81D8Q40048984-A0D0A79A-008A-466B-A8F5-9F95D6D44535Q40564541-BA004052-22E8-49C5-B64B-BB81CFAB00BEQ41139626-F1284266-A378-4B5E-BC2E-B0D0EB9D508FQ42101420-F6E4D0BE-8B2A-487C-AF94-7798FB5149F8Q47418268-962E69EC-31CB-4134-9F6E-46980F886392Q54340834-F85B99AA-D91E-424A-A1AF-C38DAB945647Q56373501-10628924-F5F5-49CC-8D28-ABFFDC627785Q64236635-0459B2C0-9EE5-40FE-A134-D9C8FC601B88Q90191213-4A6A3E73-7C00-4061-9901-8AD25676DE25Q90763598-CCEB2574-8E82-439A-B417-7DEBC01D9AA5Q91245289-9CEB0768-ADF8-49C0-90FB-4F45CB16B2B5
P50
description
researcher ORCID: 0000-0001-6089-5828
@en
name
Marco Romano
@ast
Marco Romano
@en
Marco Romano
@es
Marco Romano
@nl
type
label
Marco Romano
@ast
Marco Romano
@en
Marco Romano
@es
Marco Romano
@nl
prefLabel
Marco Romano
@ast
Marco Romano
@en
Marco Romano
@es
Marco Romano
@nl
P106
P1153
56334893100
P21
P31
P496
0000-0001-6089-5828